NRAS Q61 (Q28371022)

From Wikidata

Jump to navigation Jump to search

genetic variant

Q61
GLN61

Language	Label	Description	Also known as
English	NRAS Q61	genetic variant	Q61 GLN61

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/94

human chromosome 1

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/94

115256528

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/94

115256530

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/94

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/94

positive therapeutic predictor for

medical condition treated

determination method

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1226

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

negative therapeutic predictor for

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/14

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/124

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

cetuximab / chemotherapy combination therapy

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/36

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

positive diagnostic predictor for

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/10

NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.

negative prognostic predictor for

follicular thyroid cancer

determination method

CIViC evidence level B

CIViC 2-star trust rating

statement disputed by

Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6959

Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/94

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371022&oldid=2014798334"